Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Moodys
Baxter
AstraZeneca
Medtronic

Last Updated: November 28, 2022

Details for Patent: 8,283,380


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,283,380 protect, and when does it expire?

Patent 8,283,380 protects XADAGO and is included in one NDA.

This patent has forty-four patent family members in twenty-six countries.

Summary for Patent: 8,283,380
Title:Methods for treatment of parkinson's disease
Abstract: New uses of safinamide, safinamide derivatives and MAO-B inhibitors in novel types of treatment for Parkinson's Disease are described. More specifically, the invention relates to methods for treating Parkinson's Disease through the administration of safinamide, a safinamide derivative, or a MAO-B inhibitor, in combination with other Parkinson's Disease agents or treatments, such as levodopa/PDI or dopamine agonists.
Inventor(s): Fariello; Ruggero (Luino, IT), Cattaneo; Carlo (Milan, IT), Salvati; Patricia (Arese, IT), Benatti; Luca (S. Maurizio al Lambro, IT)
Assignee: Newron Pharmaceuticals S.p.A. (Bresso, IT)
Application Number:10/559,982
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,283,380
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,283,380

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mdd Us XADAGO safinamide mesylate TABLET;ORAL 207145-001 Mar 21, 2017 RX Yes No See Plans and Pricing See Plans and Pricing ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING 'OFF' EPISODES See Plans and Pricing
Mdd Us XADAGO safinamide mesylate TABLET;ORAL 207145-002 Mar 21, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING 'OFF' EPISODES See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,283,380

PCT Information
PCT FiledApril 08, 2004PCT Application Number:PCT/IB2004/001408
PCT Publication Date:October 21, 2004PCT Publication Number: WO2004/089353

International Family Members for US Patent 8,283,380

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 044007 See Plans and Pricing
Austria 435012 See Plans and Pricing
Australia 2004228782 See Plans and Pricing
Brazil PI0409364 See Plans and Pricing
Canada 2523188 See Plans and Pricing
China 102274517 See Plans and Pricing
China 1771030 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Moodys
Express Scripts
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.